Clin2
NCT07375953Worth exploringRecruiting

Repeated clot-busting drug for stroke within 3 hours

Ischemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests if giving a second dose of a clot-busting drug (tenecteplase) helps people who had a stroke and didn't improve much after the first dose. You must receive the second dose within 4.5 hours of your stroke symptoms starting.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
120 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You are 18 or older
  • You had a stroke and got standard clot-busting medicine within 3 hours of symptoms starting
  • Your stroke symptoms were moderate to severe (NIHSS score 4 or more) before the first treatment
  • One hour after the first treatment, your symptoms didn't get much better (NIHSS improvement of 2 points or less) or they got worse, and a brain scan ruled out bleeding
  • You can get the second dose of the study drug within 4.5 hours of your stroke symptoms starting
  • This is your first stroke, or you had a prior stroke with no lasting major disability (mRS score 0 or 1)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07375966Recruiting· Phase 2
Repeated clot-busting drug for stroke with large vessel block

This trial tests if giving a second dose of the clot-busting drug tenecteplase can help people whose stroke symptoms don't improve after the first dose, when a large or medium artery in the brain is still blocked. It may be an option for patients who cannot have a mechanical clot removal procedure.

Shenyang, Liaoning
NCT06010628Recruiting· Phase 4
Tenecteplase for stroke 4.5 to 6 hours after onset

This trial tests a medicine called tenecteplase (a clot-buster) for people who have a moderate or severe stroke caused by a clot and can be treated 4.5 to 6 hours after symptoms start. It aims to see if this medicine can help improve recovery.

Shenyang, None Selected
NCT07550296Recruiting· Phase 2
Second IV Clot-Dissolving Treatment for Major Stroke

This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.

Shenyang, None Selected
NCT06320431Recruiting· Phase 3
Clot-busting drug for disabling stroke within 4.5 hours

This trial tests a clot-busting drug called tenecteplase for people having a disabling ischemic stroke (a clot blocking blood flow to the brain). It aims to see if the drug can help improve recovery when given within 4.5 hours of symptoms starting.

Sydney, Barangaroo
NCT06954155Recruiting· Phase 3
Tenecteplase for stroke treatment 24-72 hours after symptoms start

This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.

Beijing
NCT06801054Not yet recruiting· Phase 1
Second dose of tenecteplase for stroke not responding to first

This trial is testing whether a second dose of a clot-busting drug called tenecteplase can help people who are having a stroke and didn't get better after the first dose. The goal is to see if the extra dose is safe and effective.

Houston, Texas

Hear when a new Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.